Cajal Comes Out of Stealth with $96M for Alzheimer's, Parkinson's Drug Discovery

NOVEMBER 29, 2022

Luke Timmerman writes about Cajal's Series A raise on the Timmerman Report - read more at link above.

“All outstanding work, in art as well as in science, results from immense zeal applied to a great idea.”